GLAB Stock Overview
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Gemina Laboratories Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.50 |
| 52 Week High | CA$0.65 |
| 52 Week Low | CA$0.20 |
| Beta | 0.31 |
| 1 Month Change | 0% |
| 3 Month Change | -7.41% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 17.65% |
Recent News & Updates
Shareholder Returns
| GLAB | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 25.0% | -1.1% | 0.7% |
| 1Y | n/a | -38.2% | 5.5% |
Return vs Industry: Insufficient data to determine how GLAB performed against the Canadian Biotechs industry.
Return vs Market: Insufficient data to determine how GLAB performed against the Canadian Market.
Price Volatility
| GLAB volatility | |
|---|---|
| GLAB Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 13.4% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.2% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: GLAB has not had significant price volatility in the past 3 months.
Volatility Over Time: GLAB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Brian Firth | www.geminalabs.com |
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops Legio X, a COVID-19 rapid antigen test that validating the Gemina Surface Chemistry on this platform; and LEGIO X, an influenza AB multiplex lateral flow test. It is also developing a pipeline of products for the diagnosis of infectious respiratory diseases.
Gemina Laboratories Ltd. Fundamentals Summary
| GLAB fundamental statistics | |
|---|---|
| Market cap | CA$36.89m |
| Earnings (TTM) | -CA$6.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs GLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAB income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$6.41m |
| Earnings | -CA$6.41m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.087 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -29.8% |
How did GLAB perform over the long term?
See historical performance and comparison